<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853589</url>
  </required_header>
  <id_info>
    <org_study_id>1049/2021</org_study_id>
    <nct_id>NCT04853589</nct_id>
  </id_info>
  <brief_title>Effect of Hyaluronic Acid on the Therapy of Alveolar Osteitis</brief_title>
  <official_title>Effect of Hyaluronic Acid on the Therapy of Alveolar Osteitis - A Double-blind, Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alveolar osteitis (AO; syn. dry socket) is one of the most frequent complications following&#xD;
      tooth removal and it is defined as presence of severe postoperative pain in and around the&#xD;
      extraction site, which increases in severity at any time between one and three days after&#xD;
      extraction, accompanied by a partially or completely disintegrated blood cloth within the&#xD;
      alveolar socket, with or without halitosis, and at the same time excluding any other cause&#xD;
      for the pain (Blum 2002). To enhance standard treatment of AO, which consists of curettage of&#xD;
      the dry socket, rinsing with saline solution, and inducing bleeding from the exposed alveolar&#xD;
      bone walls, numerous products have been tested. One of them is hyaluronic acid (HY). The aim&#xD;
      of the present study is to investigate the potential effect of HY gel application in the&#xD;
      treatment of AO. Specifically, the application of HY only (HY test group; n = 20) or the&#xD;
      combination of HY and an absorbable collagen sponge (HY+C test group; n = 20) will be&#xD;
      compared to standard treatment (blood clot; control group, n=20). Clinical and patient&#xD;
      related outcome parameters will be recorded for up to 14 days after treatment. A more stable&#xD;
      blood clot and thus improved wound healing with faster pain reduction is expected through the&#xD;
      use of HY.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain perception by the patient</measure>
    <time_frame>2 weeks</time_frame>
    <description>VAS- Visual analogue scale measured on a 10cm scale, where 0 represents no pain and 10 represents maximum pain</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alveolar Osteitis</condition>
  <arm_group>
    <arm_group_label>Hyaluronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hyaluronic acid gel application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic acid+carrier</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hyaluronic acid gel application together with a carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard treatment (i.e., blood clot only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid gel</intervention_name>
    <description>After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 1 will receive hyaluronic acid gel.</description>
    <arm_group_label>Hyaluronic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid gel + carrier</intervention_name>
    <description>After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 2 will receive hyaluronic acid gel together with a collagen carrier.</description>
    <arm_group_label>Hyaluronic acid+carrier</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt; 18 years;&#xD;
&#xD;
          2. Untreated AO after extraction of a permanent tooth (excluding wisdom teeth);&#xD;
&#xD;
          3. Diagnosis of AO based on the criteria of Blum (Blum 2002)&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
          4. Patients with chronic diseases and/or taking any medication, influencing hard and soft&#xD;
             tissue healing;&#xD;
&#xD;
          5. Pregnancy;&#xD;
&#xD;
          6. History of hypersensitivity or allergy to HY;&#xD;
&#xD;
          7. Inability to attend follow-up appointments; Intake of preoperative antibiotics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danijel Domic, DMD</last_name>
    <phone>+4369917230592</phone>
    <email>Danijel.domic@meduniwien.ac.at</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Danijel Domic DMD</investigator_full_name>
    <investigator_title>Dental medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteitis</mesh_term>
    <mesh_term>Dry Socket</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

